Liraglutide is under clinical development by Novo Nordisk and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Liraglutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Liraglutide (Victoza) is a potent anti-diabetic agent. It is the first and only human GLP-1 analog drug, synthesized by recombinant DNA expression in the species saccharomyces cerevisiae and has been engineered bio-technologically to be about 97 percent homologous to the Glucagon like peptide 1 (GLP-1) expressed in the humans through the substitution of lysine at 34th position with arginine. It is formulated as solution for subcutaneous route of administration and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non- fatal myocardial infarction, or non- fatal stroke) in adults with type 2 diabetes mellitus, established cardiovascular disease and indicated for the treatment of pediatric patients of 10 years or older with type 2 diabetes.
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis, Parkinson's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic arthritis and also as an adjunct therapy to insulin in Type 1 diabetes.
Novo Nordisk overview
Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
For a complete picture of Liraglutide’s drug-specific PTSR and LoA scores, buy the report here.